Hadassah

Hadassah’s Prof. Eitan Kerem Receives European Cystic Fibrosis Society 2014 Prize

Thursday, Jun 19 2014

Prof. Eitan Kerem, world-renowned cystic fibrosis specialist and head of the Hadassah Medical Organization’s Division of Pediatrics, has been awarded the European Cystic Fibrosis Society (ECFS)’s 2014 prize for his outstanding work in CF.

Prof. Kerem is the principal investigator of many national and international multi-center clinical trials and author of over 170 papers in the field of pulmonology. His research spans such topics as the association between phenotype and genotype, prediction of disease severity and mortality, molecular mechanisms that affect variability in disease, and development of new mutation-specific pharmacological therapies to correct the basic defects in CF. Prof. Kerem was also instrumental in formulating the guidelines that paved the road toward the standardization of CF care in Europe and other parts of the world.

At the same time, Prof. Kerem has been a leader in promoting the rights of children with chronic diseases and advocating for proper care of these children. He has also been at the forefront of building bridges to peace through medicine, sharing his expertise with Palestinian colleagues and promoting professional exchanges between Palestinians and Israelis.

Prof. Kerem has served as Chairman of the Medical Advisory Board of Israel’s CF Foundation and on the board of the ECFS, as well as president of the International Congress on Pediatric Pulmonology.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More